VADS INDUCE-3 (GSK-209229) Study of GSK3359609 and Pembrolizumab in Programmed Death Receptor 1-ligand 1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (INDUCE-3) Paris CHRISTOPHE LE TOURNEAU
VADS INDUCE-4 (GSK-209227) A Randomized, Double-Blind, Adaptive, Phase II/III Study of GSK3359609 in Combination With Pembrolizumab and 5FU-Platinum Chemotherapy Versus Placebo in Combination With Pembrolizumab Plus 5FU-Platinum Chemotherapy for First-Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma. Paris CHRISTOPHE LE TOURNEAU
VADS M19-894 A Phase 1b, Multicenter, Open-Label Study to Determine the Safety, Tolerability,;Pharmacokinetics, and Preliminary Efficacy of ABBV-368 plus Tilsotolimod and Other Therapy;Combinations in Subjects with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Paris CHRISTOPHE LE TOURNEAU
VADS SKYSCRAPER-09 (BO42533) A Phase II, Randomized, Double Blind Study of Atezolizumab Plus Tiragolumab and Atezolizumab Plus Placebo as First-Line Treatment in Patients With Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck. Paris CHRISTOPHE LE TOURNEAU
VADS HPV.DCVax Multicentric randomized phase I/IIa trial of the safety and immunogenicity of a;therapeutic anti-HPV DC targeting vaccine in patients with Human papillomavirus;(HPV)-positive oropharyngeal cancer. Paris CHRISTOPHE LE TOURNEAU
VADS TG4050.02 A randomized phase I trial in patients with newly-diagnosed, locoregionally advanced, HPV-negative, squamous cell carcinoma of the head and neck (SCCHN);evaluating a mutanome-directed immunotherapy;initiated at completion of primary treatment or at time of recurrence Paris CHRISTOPHE LE TOURNEAU
VADS BGB-HNSCC-201 A Randomized, Phase 2, Open-Label, Multi-Arm;Study of Tislelizumab in Combination With;Investigational Agents as First-Line Treatment in;Patients With Recurrent or Metastatic Head and Neck;Squamous Cell Carcinoma. Paris CHRISTOPHE LE TOURNEAU
VADS 219885 219885 GALAXIES H&N-202 A Phase 2, Randomized, Open-label, Platform Study Using a Master Protocol to Evaluate Novel Immunotherapy Combinations as First-Line Treatment in Participants with Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck Paris CHRISTOPHE LE TOURNEAU
VADS MIBI-THYR Value of the Combination Ultrasonography With Ti-RADS Score / Dual Tracer Scintigraphy MIBI-Tc99m/Iodine-123 in the Detection of Malignancy of Thyroid Nodules (Sup or Egal to 15 mm) Classified Bethesda III or IV on Cytology. Saint-Cloud
VADS Nanoray-312 A Phase 3 Study of NBTXR3 Activated by Investigator's Choice of Radiotherapy Alone or Radiotherapy in Combination With Cetuximab for Platinum-based Chemotherapy-Ineligible Elderly Patients With LA-HNSCC Paris CAROLINE HOFFMANN